Australia Court Rules For Pfizer In Ranbaxy Lipitor Patent Suit
This article was originally published in PharmAsia News
Australia's federal court ruled in favor of Pfizer in a case that had challenged its patent for atorvastatin, Lipitor's active ingredient. The same court, however, declared invalid Pfizer's patent for the calcium salt that is part of atorvastatin. Ranbaxy Laboratories, which sought to make a generic version of the drug, had challenged the patent, which now is valid through 2012. Pfizer says it could appeal the court's ruling on the calcium salt patent. (Click here for more
You may also be interested in...
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.